EPO and acute myeloid leukemia: Also, during the first 24 weeks, 11 patients in the epoetin-α group (12.9%), and 4 patients in the placebo group (8.9%) experienced disease progression, including 53 [3.5%] AML progressions in the epoetin-α group and 2 [4.4%] in the placebo group.